Management of adverse events associated with TROP2-targeted antibody-drug conjugates in cancer patients

Abstract

Antibody-drug conjugates (ADCs) constitute an innovative category of anti-tumor therapeutics that selectively deliver cytotoxins to tumor cells, improving efficacy and reducing toxicity in comparison to systemic therapy. TROP2 serves as a significant target for ADCs in cancer detection and treatment. TROP2-targeted ADCs have shown promising efficacy in cancer therapy. However, it is essential to monitor expected adverse effects to ensure the anti-tumor efficacy and safety. This review clarifies the mechanisms and toxicological profiles of TROP2-targeted medicines based on clinical trials and recommendations, with the aim of providing solutions for the prevention, detection, and management of related adverse events.